Know Cancer

forgot password

Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma

Phase 2
18 Years
Not Enrolling
Multiple Myeloma and Plasma Cell Neoplasm

Thank you

Trial Information

Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma



- To determine the safety and efficacy, as determined by response rate (complete response
[CR] + near CR + partial response), of lenalidomide administered with rituximab in
patients with relapsed and/or refractory CD20+ multiple myeloma.


- To assess the effects of this regimen on patient lymphocyte subsets (T, B, and NK
cells) in peripheral blood and bone marrow samples from these patients.

- To perform detailed phenotypic analyses of NK cells in patient blood and bone marrow
samples at baseline and post-treatment.

OUTLINE: Patients receive oral lenalidomide once daily on days 1-21. Treatment with
lenalidomide repeats every 28 days for at least 4 courses. Patients also receive rituximab
IV once weekly in weeks 2-5 and in week 13. Patients with stable disease then receive
rituximab once every 8 weeks. Treatment continues in the absence of disease progression or
unacceptable toxicity.

Peripheral blood samples are collected at baseline, and after courses 2 and 4. Samples are
examined by flow cytometry for lymphocyte subset analysis (T-, B-, and NK-cell percentages
and absolute numbers) and NK-cell phenotyping (CD16, CD56, NKG2D expression). Samples are
also examined by immunologic assays of isolated peripheral blood mononuclear cells. Bone
marrow aspirate samples are also collected at baseline and after course 2. Bone marrow
mononuclear cells are isolated and evaluated by CD138+ plasma cell selection, ex vivo
antibody-dependent cellular cytotoxicity assays, and bone marrow lymphocyte subset analysis.

After completion of study therapy, patients are followed at 30 days.

Inclusion Criteria


- Histologically confirmed CD20+ multiple myeloma

- CD20+ disease defined as co-expression of CD20 on ≥ 25% of the clonal plasma
cell population as defined by immunohistochemical or flow cytometric staining of
a bone marrow or plasmacytoma specimen obtained at study entry

- For flow cytometry, this is determined by calculating the frequency of
CD20+ CD138+ double-positive cells within the total CD138+ plasma cell

- For immunohistochemistry, this is determined by dual staining for CD20 and
the involved clonal light chain (kappa or lambda), with a determination of
the percent double-positive (≤ 25% or ≥ 25%)

- Symptomatic multiple myeloma that has relapsed or progressed after at least 1 prior
anti-myeloma therapeutic regimen


- ECOG performance status 0-2

- Life expectancy > 16 weeks (4 months)

- ANC ≥ 1,500/μL (unless low ANC due to multiple myeloma)

- Platelets ≥ 100,000/μL (unless low platelets are due to multiple myeloma)

- Serum bilirubin ≤ 2.0 mg/dL

- AST, ALT, and alkaline phosphatase < 3 times upper limit of normal

- Serum creatinine ≤ 2.5 mg/dL

- Able to understand the investigational nature of lenalidomide and rituximab
combination therapy and to give informed consent

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception at least 28 days
before, during, and for at least 28 days after completion or discontinuation of study

- Able to take acetylsalicylic acid (ASA) (325 mg) daily as prophylactic
anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight

- Prior malignancies with a disease free interval of ≥ 5 years allowed

- No history of thromboembolic disease within the past 6 months, regardless of

- No myocardial infarction within the past 6 months

- No New York Hospital Association class III or IV heart failure

- No uncontrolled angina

- No severe uncontrolled ventricular arrhythmias

- No active hepatitis B or C infection

- No HIV 1or 2 positivity

- No acute ischemia or active conduction system abnormalities as evidenced by ECG

- No history of hypersensitivity reactions to lenalidomide, thalidomide, or rituximab

- No other medical condition or laboratory evaluation that, in the treating physician's
or principal investigators' opinion, makes the patient unsuitable to participate in
this clinical trial

- No concurrent active malignancy other than nonmelanoma skin cancers or
carcinoma-in-situ of the cervix


- At least 3 weeks since prior therapy, including radiotherapy

- Prior lenalidomide or thalidomide allowed

- No prior rituximab

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Final response rate after 4 courses of treatment

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Hani Hassoun, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:

Mskcc 07-070



Start Date:

November 2007

Completion Date:

February 2009

Related Keywords:

  • Multiple Myeloma and Plasma Cell Neoplasm
  • refractory multiple myeloma
  • Neoplasms
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021